Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the Eur...

Descripción completa

Detalles Bibliográficos
Autores principales: Okikiolu, Jumoke, Woodley, Claire, Cadman-Davies, Llywelyn, O'Sullivan, Jennifer, Radia, Deepti, Garcia, Natalia Curto, Harrington, Patrick, Kordasti, Shahram, Asirvatham, Susan, Sriskandarajah, Priya, Saunders, Jamie, Saha, Chandan, Sanchez, Irene, deLavallade, Hugues, McLornan, Donal P, Harrison, Claire N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801096/
https://www.ncbi.nlm.nih.gov/pubmed/36590864
http://dx.doi.org/10.1016/j.lrr.2022.100360
Descripción
Sumario:Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.

Ejemplares similares